Please use this identifier to cite or link to this item:
|Title:||Value based pricing for NHS drugs: An opportunity not to be missed?|
|Publisher:||British Medical Journal|
|Citation:||BMJ 336(7638): 251-254, Feb 2008|
|Abstract:||The policy debate about price, value, and innovation in pharmaceuticals is at a critical stage for the NHS. Karl Claxton and colleagues describe the key principles of value based pricing and consider some of the concerns about such a scheme|
|Description:||The official puclished version of the article can be found at the link below|
|Appears in Collections:||Health Economics Research Group (HERG)|
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.